Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma
By: Retzloff LB, Heinzke L, Figureoa SD, Sublett SV, Ma L, Sieckman GL, Rold TL, Santos I, Hoffman TJ, Smith CJ.

Radiopharmaceutical Sciences Institute, 143 Major Hall, University of Missouri, Columbia, MO 65211, USA.
Anticancer Res. 2010 Jan; 30(1):19−30.

Abstract

Background

Gastrin−releasing peptide (GRP) receptors are overexpressed on a variety of human carcinomas, including those of the breast. These receptors may be targeted with bombesin (BBN), which binds to GRP receptors with high affinity and specificity. The aim of this study was to develop a (99m)Tc(I)−BBN analog with favorable pharmacokinetic properties in order to improve the visualization of breast cancer tissue.

Materials And Methods

Solid−phase peptide synthesis was used to produce a series of X−Y−BBN−NH2 conjugates, where X is pyrazolyl (PZ1) or 2,3−diaminopropionic acid (DPR) and Y is a spacer sequence. Their metallated counterparts were prepared by reacting [(99m)Tc−(H(2)O)(3)(CO)(3)](+) with the corresponding ligand.

Results

While the PZ1 conjugates exhibited higher GRP receptor binding affinities in vitro, the DPR analogs demonstrated superior target tissue accumulation and pharmacokinetic properties in vivo.

Conclusion

These results demonstrate the ability of the DPR derivatives (Y=glycylserylglycine, triserine) to clearly identify the T47−D tumor tissue in xenografted SCID mice.

PMID: 20150613 [PubMed − indexed for MEDLINE] Source: National Library of Medicine.






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements